SI3213750T1 - Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C - Google Patents

Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C

Info

Publication number: SI3213750T1
Authority: SI; Slovenia
Prior art keywords: antivirals; combination; treating hepatitis; hepatitis; treating
Prior art date: 2013-03-14

Application number

SI201431674T

Other languages

English (en)

Inventor

Barry M. Bernstein

Sandeep Dutta

Wei Liu

Thomas J. Podsadecki

Andrew L. Campbell

Rajeev M. Menon

Chih-Wei Lin

Tianli Wang

Walid M. Awni

Sven Mensing

Original Assignee

Abbvie Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2014-03-14

Publication date

2020-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3213750(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Abbvie Inc. filed Critical Abbvie Inc.

2020-11-30 Publication of SI3213750T1 publication Critical patent/SI3213750T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SI201431674T 2013-03-14 2014-03-14 Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C SI3213750T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361783376P	2013-03-14	2013-03-14
EP17165207.6A EP3213750B1 (en)	2013-03-14	2014-03-14	Combination of two antivirals for treating hepatitis c

Publications (1)

Publication Number	Publication Date
SI3213750T1 true SI3213750T1 (sl)	2020-11-30

Family

ID=50588882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201431674T SI3213750T1 (sl)	2013-03-14	2014-03-14	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C
SI201430265A SI2968301T1 (sl)	2013-03-14	2014-03-14	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI201430265A SI2968301T1 (sl)	2013-03-14	2014-03-14	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C

Country Status (26)

Country	Link
US (1)	US20140275099A1 (sl)
EP (3)	EP3213750B1 (sl)
JP (4)	JP6441303B2 (sl)
KR (2)	KR20210013344A (sl)
CN (2)	CN105073113B (sl)
AU (2)	AU2014239563B2 (sl)
BR (1)	BR112015023017B1 (sl)
CA (1)	CA2901810C (sl)
CY (2)	CY1119025T1 (sl)
DK (2)	DK2968301T3 (sl)
EA (2)	EA033257B1 (sl)
ES (2)	ES2824473T3 (sl)
HK (2)	HK1244668A1 (sl)
HR (2)	HRP20171036T1 (sl)
HU (2)	HUE052113T2 (sl)
IL (1)	IL240419B (sl)
LT (2)	LT2968301T (sl)
MX (2)	MX362616B (sl)
NZ (2)	NZ631155A (sl)
PL (2)	PL3213750T3 (sl)
PT (2)	PT2968301T (sl)
RS (2)	RS56202B1 (sl)
SG (2)	SG10201708306WA (sl)
SI (2)	SI3213750T1 (sl)
TW (2)	TWI642436B (sl)
WO (1)	WO2014152514A1 (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
SI3213750T1 (sl)	2013-03-14	2020-11-30	Abbvie Inc.	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C
JP2016523924A (ja) *	2013-07-02	2016-08-12	アッヴィ・インコーポレイテッド	Ｈｃｖの治療方法
CN105658219A (zh) *	2013-10-25	2016-06-08	艾伯维公司	用于治疗hcv的方法
EP3082808A1 (en) *	2013-12-19	2016-10-26	AbbVie Inc.	Methods for treating liver transplant recipients
MX2016012722A (es) *	2014-04-02	2016-12-16	Abbvie Inc	Metodos para tratar el virus de la hepatitis c.
MX2016012799A (es) *	2014-04-02	2016-12-12	Abbvie Inc	Metodos para tratar el virus de la hepatitis c.
CR20180030A (es) *	2015-06-26	2018-05-24	Abbvie Inc	Composiciones farmacéuticas sólidas para el tratamiento del vhc.
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
US20230385268A1 (en) *	2022-05-17	2023-11-30	Abbvie Inc.	Methods for Treating HCV
US20180177779A1 (en) *	2015-07-08	2018-06-28	Abbvie Inc.	Methods for Treating HCV
CA2992722C (en) *	2015-07-17	2023-10-17	Abbvie Inc.	Solid pharmaceutical compositions for treating hcv
US11192914B2 (en)	2016-04-28	2021-12-07	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
AU2017332771A1 (en) *	2016-09-23	2019-04-04	Abbvie Inc.	Dose adjustment
JP2018131439A (ja) *	2017-02-14	2018-08-23	アッヴィ・インコーポレイテッド	Ｈｃｖを処置する方法
CA2981993A1 (en) *	2017-08-02	2019-02-02	Abbvie Inc.	Methods for treating hcv
CN112351799A (zh) *	2018-04-10	2021-02-09	阿堤亚制药公司	具有硬化的hcv感染患者的治疗
WO2020106835A1 (en)	2018-11-20	2020-05-28	Abbvie Inc.	Methods for treating acute hcv
KR102077833B1 (ko)	2018-12-10	2020-02-14	류형준	기능성 식품조성물
CN111688355B (zh)	2019-03-15	2022-04-12	精工爱普生株式会社	液体吸收体、液体吸收器以及液体喷出装置
SG11202111196RA (en) *	2019-04-08	2021-11-29	Abbvie Inc	Solid pharmaceutical compositions for treating hcv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8937150B2 (en) *	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en) *	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
SG188618A1 (en) *	2010-09-21	2013-04-30	Enanta Pharm Inc	Macrocyclic proline derived hcv serine protease inhibitors
US8330139B2 (en)	2011-03-25	2012-12-11	Micron Technology, Inc.	Multi-level memory cell
CH707029B1 (de)	2011-10-21	2015-03-13	Abbvie Inc	Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
AU2013201532B2 (en)	2011-10-21	2014-10-02	Abbvie Ireland Unlimited Company	Methods for treating HCV
HUE046544T2 (hu) *	2012-09-18	2020-03-30	Abbvie Inc	Eljárások Hepatitis C kezelésére
SI3213750T1 (sl)	2013-03-14	2020-11-30	Abbvie Inc.	Kombinacija dveh antivirusnih sredstev za zdravljenje hepatitisa C

2014
- 2014-03-14 SI SI201431674T patent/SI3213750T1/sl unknown
- 2014-03-14 EA EA201591702A patent/EA033257B1/ru unknown
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/zh not_active Expired - Fee Related
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/hu unknown
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/ja active Active
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/zh active Pending
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/ko active Application Filing
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en active Application Filing
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 ES ES17165207T patent/ES2824473T3/es active Active
- 2014-03-14 SI SI201430265A patent/SI2968301T1/sl unknown
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/ko active IP Right Grant
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 RS RS20170672A patent/RS56202B1/sr unknown
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/en active
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/pt active IP Right Grant
- 2014-03-14 PL PL17165207T patent/PL3213750T3/pl unknown
- 2014-03-14 PT PT147199772T patent/PT2968301T/pt unknown
- 2014-03-14 MX MX2015012538A patent/MX362616B/es active IP Right Grant
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/lt unknown
- 2014-03-14 EA EA201991174A patent/EA201991174A1/ru unknown
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/lt unknown
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/da active
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/es active Active
- 2014-03-14 PT PT171652076T patent/PT3213750T/pt unknown
- 2014-03-14 TW TW103109530A patent/TWI642436B/zh not_active IP Right Cessation
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 PL PL14719977T patent/PL2968301T3/pl unknown
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 RS RS20201198A patent/RS60881B1/sr unknown
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 TW TW107108651A patent/TWI686196B/zh not_active IP Right Cessation
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/es unknown
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
- 2016-07-20 HK HK18103210.8A patent/HK1244668A1/zh unknown
- 2016-07-20 HK HK16108631.0A patent/HK1223817A1/zh unknown
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/el unknown
- 2017-07-06 HR HRP20171036TT patent/HRP20171036T1/hr unknown
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/ja active Active
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/ja active Pending
2020
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/hr unknown
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/el unknown
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/ja active Pending

Also Published As

Publication number	Publication date
SG10201708306WA (en)	2017-11-29
HK1244668A1 (zh)	2018-08-17
JP6621902B2 (ja)	2019-12-18
EA201991174A1 (ru)	2020-01-31
MX2020005054A (es)	2020-08-20
BR112015023017B1 (pt)	2022-08-30
ES2824473T3 (es)	2021-05-12
EP3213750A1 (en)	2017-09-06
TW201834656A (zh)	2018-10-01
CA2901810A1 (en)	2014-09-25
LT3213750T (lt)	2020-10-26
PL3213750T3 (pl)	2020-12-14
EP3766495A1 (en)	2021-01-20
CY1123387T1 (el)	2021-12-31
IL240419B (en)	2019-03-31
PT2968301T (pt)	2017-07-17
HRP20171036T1 (hr)	2017-10-06
AU2016202823B2 (en)	2017-11-23
PT3213750T (pt)	2020-10-19
JP2021130720A (ja)	2021-09-09
SI2968301T1 (sl)	2017-07-31
HUE033010T2 (en)	2017-11-28
WO2014152514A1 (en)	2014-09-25
TWI642436B (zh)	2018-12-01
CN105073113B (zh)	2018-01-02
DK2968301T3 (en)	2017-07-24
DK3213750T3 (da)	2020-10-19
JP2016513695A (ja)	2016-05-16
CN105073113A (zh)	2015-11-18
JP2020037589A (ja)	2020-03-12
KR20210013344A (ko)	2021-02-03
CN108159393A (zh)	2018-06-15
MX2015012538A (es)	2016-02-10
JP6441303B2 (ja)	2018-12-19
TWI686196B (zh)	2020-03-01
RS60881B1 (sr)	2020-11-30
HRP20201575T1 (hr)	2020-12-11
BR112015023017A2 (pt)	2017-07-18
EA033257B1 (ru)	2019-09-30
RS56202B1 (sr)	2017-11-30
EP3213750B1 (en)	2020-08-12
KR20150129032A (ko)	2015-11-18
IL240419A0 (en)	2015-09-24
AU2014239563A1 (en)	2015-08-27
KR102210935B1 (ko)	2021-02-02
LT2968301T (lt)	2017-05-25
SG11201507364SA (en)	2015-10-29
AU2014239563B2 (en)	2016-05-05
NZ631155A (en)	2016-05-27
PL2968301T3 (pl)	2017-09-29
JP2019048868A (ja)	2019-03-28
HUE052113T2 (hu)	2021-04-28
EP2968301A1 (en)	2016-01-20
EA201591702A1 (ru)	2016-09-30
EP2968301B1 (en)	2017-04-19
TW201511759A (zh)	2015-04-01
ES2624980T3 (es)	2017-07-18
US20140275099A1 (en)	2014-09-18
HK1223817A1 (zh)	2017-08-11
CY1119025T1 (el)	2018-01-10
CA2901810C (en)	2019-01-08
NZ719137A (en)	2017-11-24
AU2016202823A1 (en)	2016-05-19
MX362616B (es)	2019-01-28

Publication	Publication Date	Title
HK1223817A1 (zh)	2017-08-11	用於治療丙型肝炎的兩種抗病毒劑的組合
IL278912A (en)	2021-01-31	Improved preparations for the treatment of muscular dystrophy
HK1213886A1 (zh)	2016-07-15	用於治療心血管疾病的 -哌啶- -基苯甲酰胺衍生物
HK1209319A1 (en)	2016-04-01	Methods for treating hepatitis c
HUE050485T2 (hu)	2020-12-28	Tauopathia kezelési módszerei
EP2968273A4 (en)	2016-08-31	METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
HK1209320A1 (en)	2016-04-01	Methods for treating hepatitis c
IL241096A0 (en)	2015-11-30	Treatment methods
GB201308466D0 (en)	2013-06-19	Improved process for treatment of minewater
GB201322764D0 (en)	2014-02-05	Treating places
GB201322778D0 (en)	2014-02-05	Method of treatment
GB201314882D0 (en)	2013-10-02	Method of treatment